Vivani Medical's Type 2 Diabetes treatment, NPM-119 Subdermal Implant, receives FDA clearance for Phase 1 trial.
Vivani Medical's Type 2 Diabetes treatment NPM-119 Subdermal Implant has received FDA clearance. The company's Investigational New Drug Application (IND) for the six-month GLP-1 implant was approved, allowing the commencement of LIBERATE-1 Phase 1 trial to assess its safety, tolerability, and pharmacokinetics in type 2 diabetes patients. Vivani anticipates launching LIBERATE-1 in the second half of the year.
June 13, 2024
3 Articles